Neurol. praxi. 2022;23(5):395-399 | DOI: 10.36290/neu.2022.036

Vaccination of patients with multiple sclerosis

MUDr. Daniel Dražan1, MUDr. Tomáš Nečas2
1 DD ordinace, s. r. o., Nemocnice Jindřichův Hradec
2 Dětské oddělení, Krajská nemocnice T. Bati, a. s., Zlín

Patients with multiple sclerosis have an increased risk of acquiring and complications of vaccine-preventable infections caused by the underlying disease and its treatment. Vaccines have not been shown to cause or worsen the course of multiple sclerosis. All patients with multiple sclerosis should be properly vaccinated as indicated by age and risk factors, including immunosuppressive therapy. However, the latter is a contraindication to the administration of live vaccines.

Keywords: multiple sclerosis, vaccination, disease modifying drugs, immunosuppression.

Received: April 29, 2022; Revised: June 6, 2022; Accepted: June 21, 2022; Prepublished online: June 21, 2022; Published: October 6, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dražan D, Nečas T. Vaccination of patients with multiple sclerosis. Neurol. praxi. 2022;23(5):395-399. doi: 10.36290/neu.2022.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ČVS, 2020. Doporučení České vakcinologické společnosti ČLS JEP pro očkování proti invazivním meningokokovým onemocněním [online] [vid. 2022-04-18]. Dostupné z: https://www.vakcinace.eu/data/files/downloads/doporuceni_ockovani_imo_update_v2_finalrevize26062020.pdf.
    2. ČVS, 2021a. Aktualizace doporučení očkování proti pertusi u těhotných z 10. 6. 2021 [online] [vid. 2022-04-18]. Dostupné z: https://www.vakcinace.eu/data/files/downloads/aktpertuseockotehot10_06_2021final.pdf.
    3. ČVS, 2021 b. Doporučení České vakcinologické společnosti ČLS JEP k očkování proti chřipce [online] [vid. 2022-04-18]. Dostupné z: https://www.vakcinace.eu/data/files/downloads/doporucenicvskockovaniprotichripce_10_06_2021.pdf?openfld=news­‑doporuceni.
    4. ČVS, 2021c. Doporučenî České vakcinologické společnosti ČLS JEP pro očkování proti pneumokokovým onemocněním v dospělosti [online]. Dostupné z: https://www.vakcinace.eu/data/files/doporucenicvs_pneumo_10_11_21.pdf.
    5. ČVS, 2022. Doporučení České vakcinologické společnosti ČLS JEP (ČVS) k očkování proti onemocnění covid-19 [online] [vid. 2022-04-18]. Dostupné z: https://www.vakcinace.eu/data/files/downloads/doporucenicvskockovaniprotionemocnenicovid-19final_schvalene_21_2_2022.pdf.
    6. DeKeyse J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. Journal of the neurological sciences [online]. 1998;159(1):51-53. [vid. 2022-06-02]. ISSN 0022-510X. Dostupné z: doi:10.1016/S0022-510X(98)00139-7. Go to original source... Go to PubMed...
    7. DeStefano F, Bodenstab HM, Offit PA. Principal Controversies in Vaccine Safety in the United States. Clinical Infectious Diseases [online]. 2019;69(4):726-731 [vid. 2022-04-04]. ISSN 1058-4838. Dostupné z: doi:10.1093/CID/CIZ135. Go to original source... Go to PubMed...
    8. DeStefano F, Verstraeten T, Jackson LA, et al. Centers for Disease Control and Prevention VACCINE SAFETY DATALINK RESEARCH GROUP, NATIONAL IMMUNIZATION PROGRAM. Vaccinations and risk of central nervous system demyelinating diseases in adults. Archives of neurology [online] 2003;60(4): 504-9. ISSN 0003-9942. Dostupné z: doi:10.1001/archneur.60. 4. 504 Go to original source... Go to PubMed...
    9. Farez MF, Correale J, 2011. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Archives of neurology [online]. 2011;68(10):1267-1271 [vid. 2022-04-04]. ISSN 1538-3687. Dostupné z: doi:10.1001/ARCHNEUROL.2011.131. Go to original source... Go to PubMed...
    10. Farez MF, Correale J, Armstron MJ, et al. Practice guideline update summary: Vaccine­‑preventable infections and immunization in multiple sclerosis. Neurology [online]. 2019;93(13):584-594. [vid. 2022-04-18]. ISSN 0028-3878. Dostupné z: doi:10.1212/WNL.0000000000008157. Go to original source... Go to PubMed...
    11. Ghaderi S, Berg­‑Hansen P, Bakkern IJ, et al. Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population­‑based registry study from Norway. European Journal of Epidemiology [online]. 2020;35(4):355-362. [vid. 2022-04-18]. ISSN 15737284. Dostupné z: doi:10.1007/S10654-019-00595-2/TABLES/3. Go to original source...
    12. Hepfelmeier A, Gasperi CH, Donnachie E, Hemme B. A. large case­‑control study on vaccination as risk factor for multiple sclerosis. Neurology [online]. 2019;93(9):e908-e916. ISSN 1526632X. Dostupné z: doi:10.1212/WNL.0000000000008012. Go to original source... Go to PubMed...
    13. Hutter A, Eperon G, Lascano AM, et al. Risk of MS relapse after yellow fever vaccination. Neurology - Neuroimmunology Neuroinflammation [online]. 2020;7(4):e726. ISSN 2332-7812. Dostupné z: doi:10.1212/NXI.0000000000000726. Go to original source... Go to PubMed...
    14. Limberkova R. Spalničky - historie vakcinace. SZÚ, 2020 [online] [vid. 2022-04-18]. Dostupné z: http://www.szu.cz/spalnicky­‑historie­‑vakcinace.
    15. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. European journal of neurology [online]. 2013;20(8):1153-1160 [vid. 2022-06-02]. ISSN 1468-1331. Dostupné z: doi:10.1111/ENE.12130. Go to original source... Go to PubMed...
    16. NATIONAL MULTIPLE SCLEROSIS SOCIETY. COVID-19 Vaccine Guidance for People Living with MS [online] [vid. 2022-04-18]. 2022. Dostupné z: https://www.nationalmssociety.org/coronavirus­‑covid-19-information/covid-19-vaccine­‑guidance/Timing­‑MS­‑Medications­‑with­‑COVID-19-Vaccines.
    17. Otero­‑Romero S, Ascherio A, Lebrun­‑Frénay CH. Vaccinations in multiple sclerosis patients receiving disease­‑modifying drugs. Current Opinion in Neurology. [online]. 2021;34(3):322-328. ISSN 1350-7540. Dostupné z: doi:10.1097/WCO.0000000000000929. Go to original source... Go to PubMed...
    18. Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Practical Neurology [online]. 2020;20(6):435-445. [vid. 2022-04-04]. ISSN 14747766. Dostupné z: doi:10.1136/practneurol-2020-002527. Go to original source... Go to PubMed...
    19. Riva A, Barcella V, Benatti SV, et al. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Multiple Sclerosis Journal [online]. 2021;27(3):347-359. ISSN 14770970. Dostupné z: doi:10.1177/1352458520952310. Go to original source... Go to PubMed...
    20. Wijnands JM, Kingwell E, Zhu F, et al. Infection­‑related health care utilization among people with and without multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). [online]. 2017;23(11)1506-1516 [vid. 2022-06-02]. ISSN 1477-0970. Dostupné z: doi:10.1177/1352458516681198. Go to original source... Go to PubMed...
    21. Yap SM, Al Hinayi M, Gaughan M, et al. Vaccine hesitancy among people with multiple sclerosis. Multiple Sclerosis and Related Disorders [online]. 2021;56(September):103236. ISSN 22110356. Dostupné z: doi:10.1016/j.msard.2021.103236. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.